DTCFF 3.54 Defence Therapeutics Inc.

Stock List / Defence Therapeutics Inc.

Range:	0.4-2.3	Vol Avg:	202	Last Div:	0	Changes:	-0.05
Beta:	1.45	Cap:	0.02B	Currency:	USD	Exchange:	PNK
Sector:	Healthcare			IPO:	Tue May 18 2021	Empoloyees:
CUSIP:		CIK:		ISIN:	CA24463V1013	Country:	CA
CEO:	Mr. Sebastien Plouffe			Website:	https://defencetherapeutics.com

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Stock Details

Positive 0.33

Defence's Corporate Updates, Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics ...

newsfilecorp.com·Fri Sep 27 2024

DTCFF 3.54 Defence Therapeutics Inc.

Stock Details

Defence's Corporate Updates, Arranges Financing

Про сайт

Новини маркету

Ринки

Найкращі для покупки